Indaptus Therapeutics, Inc. Debt Securities, Available-for-sale, Realized Gain
Indaptus Therapeutics, Inc. (INDP) reported Debt Securities, Available-for-sale, Realized Gain of $24.16 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2024-03-13
- Indaptus Therapeutics, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-12-31 was $0.00.
- Indaptus Therapeutics, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-09-30 was $0.00.
- Indaptus Therapeutics, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-06-30 was $0.00.
- Indaptus Therapeutics, Inc. debt securities, available-for-sale, realized gain for the quarter ending 2022-03-31 was $24.16K.
- Indaptus Therapeutics, Inc. debt securities, available-for-sale, realized gain for fiscal 2022 was $24.16K.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month | Debt Securities, Available-for-sale, Realized Gain 9 month | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $24.16K 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $24.16K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $24.16K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $24.16K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |